ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.

Share on Pinterest Getty Images/Dragoljub Bankovic The FreeStyle Libre is a continuous glucose monitoring (CGM) system that doesn’t require a blood sample from a finger stick. It’s ...

Abbott’s FreeStyle Libre continuous glucose monitoring technology is associated with a significant reduction in the risk of hospitalization for heart complications in people with diabetes, according ...

(RTTNews) - Abbott Laboratories (ABT) Thursday announced positive data from REFLECT studies of its FreeStyle Libre continuous glucose monitoring (CGM) technology. The REFLECT studies, funded by ...

Abbott announced results from its REFLECT real-world studies that show the use of FreeStyle Libre continuous glucose monitoring (CGM) technology is associated with a significant reduction in the risk ...

Abbott Laboratories (NYSE:ABT) recently shared findings from its REFLECT real-world studies, revealing that the use of its FreeStyle Libre® continuous glucose monitoring (CGM) system is linked to ...

May 15, 2025 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from its REFLECT real-world studies that show the use of FreeStyle Libre® continuous glucose monitoring (CGM) technology ...

CGMs offer blood sugar monitoring that may be easier and more accurate than traditional methods. The Freestyle Libre is a particular brand of CGM that has been approved by the FDA. Shortly after ...

The latest version of Abbott's FreeStyle Libre continuous glucose monitor is now available via ... billed as the smallest and thinnest real-time CGM system available – sends glucose readings ...

has released findings from its REFLECT studies indicating that its FreeStyle Libre continuous glucose monitoring (CGM) technology is linked to a significant decrease in hospitalizations due to ...